Janssen gets diabetes CRL

Share this article:

The FDA issued a Complete Response Letter to Janssen, telling the drugmaker it needs more data about the experimental canagliflozin-metformin treatment for diabetes. The Johnson & Johnson subsidiary said in a statement that the FDA wants data indicating that canagliflozin—known by the brand Invokana, approved earlier this year—is as effective in the combined form as it is when used as a standalone treatment.

PMLive notes that the CRL is not much of a setback for Janssen, because doctors can prescribe the two drugs separately if they want to use them in tandem. The site also notes that the combination is not a unique one—Bristol-Myers Squibb and AstraZeneca are already marketing a dapagliflozin-metformin mix abroad under the brand Xigduo.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.